readthroughSign in
Nov 13, 2026Trial update

Alnylam's Phase 2 ALN-4324 study in type 2 diabetes is active, not recruiting

A 24-participant trial testing ALN-4324's effect on insulin sensitivity in adults with type 2 diabetes has stopped enrolling, with primary completion expected in mid-2027.

Alnylam Pharmaceuticals updated one registered trial this week.

  • A Phase 2 study of ALN-4324, an siRNA therapy, in adults with type 2 diabetes mellitus is listed as active, not recruiting. The trial began on January 15, 2026 and enrolled 24 participants, with an estimated primary completion date of May 28, 2027.1 The study is evaluating the effect of a single dose of ALN-4324 on whole-body insulin sensitivity, with the primary outcome being change from baseline in M-value, a measure of glucose infusion rate at steady state.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.